Last updated: May 25, 2026
INVANZ (ertapenem) suppliers and manufacturing sources: who makes it and where is it sourced?
INVANZ is the brand name for ertapenem, an injectable carbapenem antibiotic. As a result, “suppliers” typically breaks into (1) API producers of ertapenem and (2) finished-dose manufacturers that file/hold the NDA/BLA supply chain and produce INVANZ drug product for distribution in the U.S. The core branded product is supplied by the market authorization holder’s commercial manufacturing network, while generic supply is governed by each abbreviated approval’s manufacturing listings and inspections.
What exactly counts as “suppliers” for INVANZ?
- Drug substance (API) suppliers: companies manufacturing ertapenem active ingredient (including intermediates and final API).
- Drug product (finished sterile powder/vial) suppliers: companies producing ertapenem sterile vials under cGMP (often multiple sites).
- Contract manufacturing organizations (CMOs): firms performing sterile fill-finish, lyophilization, packaging, or bulk sterile drug product manufacturing.
- Wholesalers and distributors: U.S. channels (less relevant for IP/R&D decisions than API and drug product sites).
- Regulatory manufacturing sites: the FDA-registered sites tied to NDC-labeler and the application.
Who supplies INVANZ (ertapenem) in the U.S.?
INVANZ is supplied in the U.S. by Merck (the NDA holder for ertapenem brand products). The practical supplier list for inventory and purchasing is the set of NDC labelers that hold the product distribution rights and the FDA-registered drug product manufacturing sites associated with those NDCs.
What are the typical Merck supply-chain components for INVANZ?
- Sterile drug product manufacturing: manufacturing of ertapenem powder for injection vials, including sterile filling/processing steps (site-specific).
- Packaging and labeling: NDC-specific labeling and distribution packaging, tied to FDA registration for that site.
- API and intermediates sourcing: API production is usually multi-sourced via vetted suppliers, but the exact API nameplate suppliers are not consistently public in a way that supports a definitive list without pulling each NDC’s labeled application/manufacturing details.
Because INVANZ supplier identification depends on NDC-specific FDA manufacturing listings and labeler records, a complete supplier roster is not possible from the term “INVANZ” alone.
Which companies manufacture the ertapenem API used for INVANZ?
Ertapenem is a complex beta-lactam antibiotic with specialized synthesis, requiring control of intermediates and impurity profiles. In practice, API sourcing is often handled through:
- Global specialty API producers (contracted or long-term suppliers)
- Vertically integrated beta-lactam manufacturers with validated impurity control and antibiotic-handling capabilities
- Merck-qualified supplier networks tied to cGMP and quality agreements
A definitive list of ertapenem API suppliers for INVANZ requires mapping:
- the specific drug master file (DMF) references and cross-references, and
- the FDA drug substance manufacturing site listings tied to the NDA and each NDC.
Those data are not contained in the brand name alone.
What manufacturers make the finished INVANZ sterile vials for distribution?
Finished-dose manufacturing for injectable carbapenems is carried out under sterile and beta-lactam facility controls. The supplier set is typically identified by:
- FDA-registered drug product manufacturing sites for the INVANZ NDCs
- labeler/manufacturer indicated on package labeling
- additional CMOs used for lyophilization, bulk drug product, or sterile fill-finish
As with API, a complete and accurate “which plants/site owners supply INVANZ” list requires NDC-to-application manufacturing mapping.
Which FDA listings determine the true INVANZ supplier roster?
For a defensible supplier list, the governing sources are:
- FDA Orange Book entries for ertapenem brand NDA and labeler/NDC mapping
- FDA Drug Establishment Registration and Listing (DEPRECATED data model) and NDC Directory
- FDA inspections and facility ownership where publicly indexed
- NDA labeling and packaging manufacturer statements on product labeling
A supplier list that supports procurement, sourcing risk, or litigation is typically built from these elements, not from press statements or generic industry assumptions.
What do generic ertapenem suppliers imply for INVANZ sourcing risk?
Generic ertapenem availability can affect:
- Merck’s ability to secure supply of drug product and API intermediates.
- market pricing dynamics and substitution.
- capacity constraints for common sterile fill-finish or lyophilization lines.
But the presence of generics does not automatically identify INVANZ’s API or drug product supplier plants. It only indicates that multiple ertapenem-capable manufacturing networks exist.
How does INVANZ packaging/sterile fill-finish supplier selection affect supply continuity?
Key continuity drivers for sterile injectables:
- lyophilization and stopper/closure integrity lines
- beta-lactam cross-contamination controls
- validated water-for-injection and sterile filtration systems
- vial washing, depyrogenation, and container closure integrity testing throughput
If supply tightens, the bottleneck typically emerges at one of these sterile processing steps rather than API synthesis, depending on which step is capacity constrained in the qualifying network.
Key takeaways
- INVANZ is ertapenem in sterile injectable form.
- “Suppliers” for INVANZ should be split into API suppliers, finished-dose manufacturers, and sterile fill-finish/CMO sites.
- A complete, accurate list of named suppliers requires NDC-specific FDA manufacturing and labeler mappings plus NDA-linked API/DMF references.
- The only defensible U.S. “commercial supplier” baseline is the NDA holder Merck for brand rights, with detailed manufacturing sites requiring FDA listing cross-references.
FAQs
-
Are INVANZ suppliers the same as ertapenem generic suppliers?
Not necessarily; generic manufacturers often use different qualified API and drug product sites.
-
How can I identify INVANZ manufacturing plants from public sources?
Use INVANZ NDC-to-labeler mapping via FDA NDC Directory and then map to FDA facility registrations for drug product sites.
-
Does Merck always produce INVANZ drug product in-house?
Brand supply chains often use both company sites and contracted CMOs; plant identity is NDC- and batch-release dependent.
-
Who supplies ertapenem API for carbapenem brands like INVANZ?
API is sourced from specialized antibiotic-capable manufacturers under cGMP and quality agreements; the exact suppliers are typically discoverable only via FDA-linked filings and DMF references tied to the NDA.
-
What affects INVANZ supply disruptions most?
Sterile drug product processing capacity, lyophilization throughput, and beta-lactam facility controls often drive constraints more than final formulation steps.
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
- FDA. NDC Directory.
- FDA. Drug Establishment Registration and Listing (DE&L) system.
